Opendata, web and dolomites

MAMLE SIGNED

Understanding the mechanisms of human acute myeloid leukaemia (AML) evolution

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MAMLE" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 1˙750˙000 €
 EC max contribution 1˙750˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 1˙750˙000.00

Map

 Project objective

Acute myeloid leukemia (AML) is one of the most deadly cancers. Currently, we do not fully understand how and why AML starts or why it tends to relapse after treatment. Recent discoveries by the applicant and others have identified preleukemic stem and progenitor cells (preL-HSPCs) as the root of AML evolution. Many healthy elderly individuals carry the preleukemic mutations in their preL-HSPCs and yet, do not develop AML. It is also becoming clearer that leukemia evolution is spanning over many years but most research is focused on the late stages of the disease. Population genetics tools are specifically suited for the study of historical evolution however such tools are not well developed in the field of somatic evolution. This proposal will integrate population genetics, stem cell and leukemia biology in order to unravel human leukemia evolution from the very early preleukemic phase to relapse. Novel single cell population genetics tools will be used to describe the naive clonal structure of the human hematopoietic system in both health and disease. A unique cohort of half a million Europeans, who have been followed for years, will be used to understand why only a small fraction of the individuals carrying preleukemic mutations develop AML. Novel genetic analysis will be developed to study the clonal structure of blood cells, years before AML was diagnosed. A large cohort (N=100) of AML patients were collected serially over a year and will be collected until relapse. Detailed molecular and population genetics of this cohort will aid in understanding the mechanism of AML relapse and in developing novel molecular methodologies, that will allow early relapse diagnosis. AML like many other malignancies is diagnosed late in its evolutionary path. In this proposal the evolution of AML before diagnosis and before it relapses will be studied by novel population genetic tools so that the vision of early diagnosis and treatment will become reality.

 Publications

year authors and title journal last update
List of publications.
2018 Sagi Abelson, Grace Collord, Stanley W. K. Ng, Omer Weissbrod, Netta Mendelson Cohen, Elisabeth Niemeyer, Noam Barda, Philip C. Zuzarte, Lawrence Heisler, Yogi Sundaravadanam, Robert Luben, Shabina Hayat, Ting Ting Wang, Zhen Zhao, Iulia Cirlan, Trevor J. Pugh, David Soave, Karen Ng, Calli Latimer, Claire Hardy, Keiran Raine, David Jones, Diana Hoult, Abigail Britten, John D. McPherson, Mattias Johansson, Faridah Mbabaali, Jenna Eagles, Jessica K. Miller, Danielle Pasternack, Lee Timms, Paul Krzyzanowski, Philip Awadalla, Rui Costa, Eran Segal, Scott V. Bratman, Philip Beer, Sam Behjati, Inigo Martincorena, Jean C. Y. Wang, Kristian M. Bowles, J. Ramón Quirós, Anna Karakatsani, Carlo La Vecchia, Antonia Trichopoulou, Elena Salamanca-Fernández, José M. Huerta, Aurelio Barricarte, Ruth C. Travis, Rosario Tumino, Giovanna Masala, Heiner Boeing, Salvatore Panico, Rudolf Kaaks, Alwin Krämer, Sabina Sieri, Elio Riboli, Paolo Vineis, Matthieu Foll, James McKay, Silvia Polidoro, Núria Sala, Kay-Tee Khaw, Roel Vermeulen, Peter J. Campbell, Elli Papaemmanuil, Mark D. Minden, Amos Tanay, Ran D. Balicer, Nicholas J. Wareham, Moritz Gerstung, John E. Dick, Paul Brennan, George S. Vassiliou, Liran I. Shlush
Prediction of acute myeloid leukaemia risk in healthy individuals
published pages: 400-404, ISSN: 0028-0836, DOI: 10.1038/s41586-018-0317-6
Nature 559/7714 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAMLE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAMLE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

FatVirtualBiopsy (2020)

MRI toolkit for in vivo fat virtual biopsy

Read More  

TransTempoFold (2019)

A need for speed: mechanisms to coordinate protein synthesis and folding in metazoans

Read More  

DDREAMM (2020)

Dna Damage REsponse: Actionabilities, Maps and Mechanisms

Read More